Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

HealthDay News — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study ...

Weight management medications, like semaglutide and tirzepatide, are recommended as primary treatments for obesity to reduce cardiovascular risk. These medications outperform lifestyle ...